X Facebook LinkedIn WhatsApp Press Releases Any (-) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2024 May 7, 2024 argenx announces results of Annual General Meeting of Shareholders May 7, 2024 argenx to Present at BofA Securities 2024 Health Care Conference May 2, 2024 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 April 16, 2024 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease March 27, 2024 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease March 26, 2024 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia March 26, 2024 argenx Announces Annual General Meeting of Shareholders on May 7, 2024 March 7, 2024 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting February 29, 2024 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update February 26, 2024 argenx to Present at Upcoming Investor Conferences February 22, 2024 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024 February 20, 2024 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy Pagination Current page 1 Page 2 Next page Next › Last page Last »